¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29
±³À°ÀÏÀÚ : 2024-06-29
±³À°Àå¼Ò : ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë

±³À°ÁÖÁ¦ : 2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium

ÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѼҾƺñ´¢ÀÇÇÐȸ

´ã´çÀÚ : À̼¼Èñ
¿¬¶ôó : 02-573-8190

À̸ÞÀÏ : urology@urology.or.kr

±³À°Á¾·ù : ºñ´¢ÀÇÇаú

Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 2Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 3 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 22,000¿ø  

ºñ°í ȸºñ ³³ºÎ¿¡ µû¶ó Â÷µî ºÎ°úÇÒ ¼ö ÀÖÀ½


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 09:00~09:30 Enuresis and nocturia in an adolescence ±è¼ºÃ¶, °íÇõÁØ(¿ï»êÀÇ´ë, µ¿¾ÆÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 09:30~10:00 Overactive bladder and urinary incontinence symptoms in an adolescence ÀÓ¿µÀç, ±èµ¿¼ö(¼­¿ïÀÇ´ë, °æÈñÀÇ´ë)

Åä·Ð 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:00~10:30 Panel discussion ()

ÈÞ½Ä 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:30~10:50 Break ()

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 10:50~11:10 Management of ureterocele ÇÏÁö¿ë(°è¸íÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 11:10~11:30 Management of ureteropelvic junction obstruction (UPJO) ¹èÀçÇö(°í·ÁÀÇ´ë)

Åä·Ð 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 11:30~12:00 Panel discussion ()

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 12:00~12:15 Clinical Utility of Low-dose ¥â3-Adrenoreceptor Agonists, Mirabegron, for the Treatment of Overactive Bladder : In children(KSPU) ¼Û»óÈÆ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 29ÀÏ ºÎ»ê ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 12:15~12:30 Clinical Utility of Low-dose ¥â3-Adrenoreceptor Agonists, Mirabegron, for the Treatment of Overactive Bladder : In adult(KCS) ¹èÈ£¿µ(¿ï»êÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024³â Á¦2ȸ ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Transitional Urology Symposium : 2024-06-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦12ȸ ÀÎÁ¦ÀÇ´ë ÀÏ»ê¹éº´¿ø ½Å°æ¿Ü°ú ¿¬¼ö°­Á : 2024-06-29
´ÙÀ½±Û 2024³â ´ëÇѳëÀνŰæÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21092 ¼­¿ï ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ 2024³â ÆÀÇÇÁö¼Ç ½Ç½À °úÁ¤ Part¥° : 2024-07-07 0 53 2024-06-19
21091 ±¤ÁÖ 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ±¤ÁÖÀü³²Áöȸ ¿¬¼ö°­Á : 2024-07-07 0 28 2024-06-19
21090 ¼­¿ï 2024³â ´ëÇѼö¸é¿¬±¸ÇÐȸ Á¤±â Çмú´ëȸ DAY 2 : 2024-07-07 0 20 2024-06-19
21089 ¼­¿ï ´ëÇÑÇǺΰúÇÐȸ 2024³â Á¦4ȸ Àü¹®ÀÇ ¿¬¼ö°­Á : 2024-07-07 0 20 2024-06-19
21088 ºÎ»ê 2024 ´ëÇѺñ¸¸ÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°­Á : 2024-07-06 0 59 2024-06-18
21087 ¼­¿ï 2024 °­ºÏ»ï¼ºº´¿ø ¼ÒÈ­±â ½ÉÆ÷Áö¾ö : 2024-07-06 0 45 2024-06-18
21086 ´ëÀü Çѱ¹È£½ºÇǽº¡¤¿ÏÈ­ÀÇ·áÇÐȸ 2024³â ÇÏ°èÇмú´ëȸ : 2024-07-06 0 18 2024-06-18
21085 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2024 Á¶¿µÁ¦ ¾ÈÀü°ü¸® ½ÉÆ÷Áö¾ö : 2024-07-06 0 51 2024-06-18
21084 ¼­¿ï Á¦22ȸ ¼­¿ï½Ã ³²¼­ 7°³±¸ ÀÇ»çȸ ÇÕµ¿ Çмú´ëȸ : 2024-07-06 0 48 2024-06-18
21083 ±¤ÁÖ ±¤ÁÖÀü³²³»°úÀÇ»çȸ Á¦6ȸ ÃÊÀ½ÆÄ ÇÚÁî¿Â ¿öÅ©¼ó : 2024-07-06 0 24 2024-06-18
21082 ¼­¿ï 2024 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 51 2024-06-18
21081 °­¿ø 2024³â ´ëÇѳ»°úÇÐȸ °­¿øÁöȸ ÇÏ°è ¿¬¼ö°­Á : 2024-07-06 0 39 2024-06-18
21080 °æ±â 2024³â °í´ë¾È»ê ³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 32 2024-06-18
21079 ¼­¿ï 2024 È£Èí±â°¨¿°º´ ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 22 2024-06-18
21078 ºÎ»ê ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ&ÁöºÎ ½ÉÆ÷Áö¾ö-ºÎ¿ï°æ : 2024-07-06 0 17 2024-06-18
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷